Ispor—The Professional Society For Health Economics And Outcomes Research company information, Employees & Contact Information

NPC at ISPOR 2025 National Pharmaceutical Council

Turkish validity and reliability study of the simulation self-report cognitive load measurement tool 2.0 BMC Medical Education

Genesis Research Group announces inaugural membership of ISPOR Corporate Partnership Program GlobeNewswire

Merits of the social return on investment methodology for assessing the value of palliative care programmes The Lancet

HTA Training for Healthcare Professionals: International Overview of Initiatives Provided by HTA Agencies and Organizations Frontiers

Full article: A systematic review of pharmacoeconomic guidelines Taylor & Francis Online

Outcomes research: origins, relevance, and potential impacts for veterinary medicine AVMA Journals

A Roadmap for Increasing the Usefulness and Impact of Patient-Preference Studies in Decision Making in Health: A Good Practices Report of an ISPOR Task Force ScienceDirect.com

Zambon Announces New Data Highlighting Lifetime Burden of Illness in U.S. Patients with Bronchiolitis Obliterans Syndrome at ISPOR 2023 PR Newswire

Overcoming barriers to oncology combination therapies in the UK and EU Drug Target Review

NPC at ISPOR 2024 National Pharmaceutical Council

Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1 Taylor & Francis Online

Drug outcomes research and policies – trends and challenges Frontiers

Indirect Treatment Comparison/Network Meta-Analysis Study Questionnaire to Assess Relevance and Credibility to Inform Health Care Decision Making: An ISPOR-AMCP-NPC Good Practice Task Force Report ScienceDirect.com

Are Commercial Insurance Premiums Associated With the 340B Drug Pricing Program? National Pharmaceutical Council

Is the Scope of Costs Considered in Budget Impact Analyses for Anticancer Drugs Rational? A Systematic Review and Comparative Study Frontiers

Impacts of the Inflation Reduction Act on 2025 Formulary Coverage in Medicare Part D Plans National Pharmaceutical Council

Incorporating risk preferences of patients in the valuation of immune checkpoint inhibitors for non-small cell lung cancer Frontiers

NPC at ISPOR 2025: The Cost of 340B to States National Pharmaceutical Council

NPC at ISPOR 2025: Accelerated Approval Trends & Patient Impact National Pharmaceutical Council

Knowledge Mapping of Multicriteria Decision Analysis in Healthcare: A Bibliometric Analysis Frontiers

Aligning valid research outcomes with stakeholder values—what do they need for decision-making? Frontiers

Early Signals of Inflation Reduction Act Impact on Pharmaceutical Investment National Pharmaceutical Council

Cost-effectiveness of a machine learning risk prediction model (LungFlag) in the selection of high-risk individuals for non-small cell lung cancer screening in Spain Taylor & Francis Online

Ongoing Accelerated Approval Trends and What It Means for Patients National Pharmaceutical Council

Recommendations to overcome barriers to the use of artificial intelligence-driven evidence in health technology assessment Frontiers

Estimation of disability free life expectancy in non small cell lung cancer based on real world data Nature

How can patient preferences be used and communicated in the regulatory evaluation of medicinal products? Findings and recommendations from IMI PREFER and call to action Frontiers

A roadmap toward implementing health technology assessment in Egypt Frontiers

Pharmacoeconomic Evaluation of Cancer Biosimilars Worldwide: A Systematic Review Frontiers

Infliximab Study Yields Evidence of Biosimilar Equivalence Center for Biosimilars

Best Podium and Poster Presentations Awarded at ISPOR 22nd Annual International Meeting | Newswise Newswise

Guidance for Demonstrating the Societal Value of new Antibiotics Frontiers

Marilyn Smith McGhan Obituary October 21, 2018 Eichholtz & Daring Funeral Homes & Cremation Center

“What’s Keeping Me Up at Night?” Reflections on the COVID-19 Pandemic in Asia Cambridge University Press & Assessment

Real-World Data on A1c Reduction With Invokana Announced Medical Professionals Reference

Pulmonary Arterial Hypertension: Progress and Challenges in the Modern Treatment Era AJMC

Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries Frontiers

Ruxolitinib May Be More Cost-Effective Than BAT for Patients With Hydroxyurea Resistant/Intolerant PV AJMC

Framework for the synthesis of non-randomised studies and randomised controlled trials: a guidance on conducting a systematic review and meta-analysis for healthcare decision making BMJ Evidence-Based Medicine

Why Rater Training Matters in Clinical Trials: A Science Overview Clinical Leader

Adherence to country-specific guidelines among economic evaluations undertaken in three high-income and middle-income countries: a systematic review | International Journal of Technology Assessment in Health Care | Cambridge Core Cambridge University Press & Assessment

Development of multi-criteria decision analysis (MCDA) framework for off-patent pharmaceuticals – an application on improving tender decision making in Indonesia BMC Health Services Research

GLOBAL FOCUS: The Approval and Substitutability of Biosimilars: Potential Impact on Use and Competition Food and Drug Law Institute (FDLI)

Use of real-world evidence in cancer drug funding decisions in Canada: a qualitative study of stakeholders’ perspectives CMAJ Open

Effect of Drug Prices Control Order (DPCO), 2013 on medicines Moneylife